RxDoctor Payments Data

Richard Ferguson, PA

Physician Assistant · Irving, TXNPI 1942789086

Payments from drug & device makers

$6,736in general payments, 2019–2025

Across 392 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$811
  • Boehringer Ingelheim$719
  • Lilly USA, LLC$716
  • AstraZeneca$686
  • Novo Nordisk$505
  • GSK$503
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$6,736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,736 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$65,559
Medicare patients
279
Services billed
1,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$47,626
EliquisApixaban16$23,352
MounjaroTirzepatide12$20,463
Olmesartan Medoxomil52$1,285
Azelastine Hcl32$1,270
Albuterol Sulfate HfaAlbuterol Sulfate38$1,159
Atorvastatin Calcium57$572
Montelukast Sodium35$548
Duloxetine Hcl12$466
Doxycycline Monohydrate45$446
Celecoxib16$435
Losartan Potassium41$392
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med13$387
Amlodipine Besylate66$376
Fluticasone Propionate28$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$505$47,62643 claims
PfizerEliquis$180$23,35216 claims
Lilly USA, LLCMounjaro$716$20,46312 claims
Almatica Pharma LLCSertraline Hcl$13$8416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →